Brind.
  1. Corporate activity in the medical device sector in August 2025 included M&A activity (Stryker/Inari Medical, ZimVie/Archimed), competition between Medtronic and Intuitive Surgical, and the impact of Trump administration tariffs and FDA reviews.

Medtronic invested in Orchestra BioMed's clinical programs and provided private placement funding, while Ligand also invested in the company.

3 reports, 1 independent Updated Aug 5
Gone quiet
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Medtronic invested in Orchestra BioMed's clinical programs and provided private placement funding, while Ligand also invested in the company.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireOrchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings $56.2 million in proceed
  • GlobeNewswireLigand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed • Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue
  • Unknown outlet